权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Modulating P-glycoprotein to Enhance Neurodegenerative Drug Penetration of Brain

调节 P-糖蛋白增强神经退行性药物在大脑中的渗透

基本信息

批准号：
7329774
负责人：
CHRISTINE A HRYCYNA
金额：
$ 21.57万
依托单位：
PURDUE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-09-01 至 2009-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7329774
关键词：
ATP-Binding Cassette Transporters Address Alzheimer&apos s Disease Animals Antiepileptic Agents Biological Assay Biological Availability Blood - brain barrier anatomy Blood capillaries Brain Brain Diseases Cancer cell line Capillary Endothelial Cell Cell Line Cells Cultured Cells Daunorubicin Dose Drug resistance Endothelial Cells Environment Epilepsy Family suidae Funding Galantamine Gleevec Goals Modeling Monitor Natural regeneration Nerve Degeneration Numbers P-Glycoprotein P-Glycoproteins Paper Patients Penetration Pharmaceutical Preparations Phenobarbital Phenytoin Prodrugs Protein Overexpression Publishing Pump Qualifying Radiolabeled Rattus Research Rhodamine 123 Serum Temporal Lobe Epilepsy Therapeutic Therapeutic Agents Therapeutic Uses Valspodar Verapamil Work base calcein AM capillary dimer experience improved in vivo inhibitor/antagonist lamotrigine monomer mouse model nervous system disorder novel radiotracer research study uptake

项目摘要

DESCRIPTION (provided by applicant): In this proposal, we are investigating ways to increase the brain bioavailability of agents targeted against epilepsy and Alzheimer's disease, two common and devastating neurological disorders. We are exploring ways to reversibly modulate the activity of P-glycoprotein (P-gp) at the blood brain barrier (BBB). It has been shown in vivo that pharmacological inhibition of P-gp at the blood brain barrier by valspodar (PSC833) increased the uptake of the anti-epileptic agent phenytoin, a P-gp substrate, in brains. We propose to develop novel dimeric prodrug inhibitors of P-gp based on the therapeutic agents themselves. Once into the brain, these dimeric prodrugs will revert to the known approved therapeutic agent. We hypothesize that co-administration of the dimeric prodrug inhibitor in conjunction with therapeutic doses of the monomeric drug would serve to increase the level of the therapeutic agent in the brain and potentially lower the overall patient dose level. We believe that we have assembled a team of PIs with extensive experience to address each of the Specific Aims. Specific Aim 1: We will synthesize prodrug dimers of anti-epilepsy drugs (AEDs) (phenytoin, phenobarbital and lamotrigine), an anti-Alzheimer's disease drug (galantamine) and a potential anti- Alzheimer's disease agent (Gleevec) that are tethered via traceless linkers. Specific Aim 2: We will evaluate inhibition of P-gp transport by the prodrug dimers using various cell lines that overexpress P-gp or express P-gp at endogenous in vivo levels. Specific Aim 3: We will evaluate inhibition of P-gp transport of the fluorescent substrates daunomycin, calcein-AM, Bodipy-FL-verapamil and rhodamine 123 in isolated rat brain capillaries by the prodrug dimers and will use the therapeutic monomers as controls. At the completion of the proposed funding period, we will have dimeric prodrugs with activity against P-glycoprotein in brain endothelial cell and brain capillary models. The long term goals of this research will be to monitor brain penetration of AEDs and anti-Alzheimer's drugs in combination with the active prodrugs in an epileptic mouse model. Treating brain diseases is problematic because a number of drugs are not able to enter the brain. This lack of brain penetration is caused in part by a pump at the barrier to the brain that removes drugs before brain entry. This proposal seeks to remedy this problem by blocking the pump temporarily to allow drugs to pass into the brain. Completion of these studies has the potential to improve treatment of epilepsy and Alzheimer's disease.

描述（由申请人提供）：在本提案中，我们正在研究如何提高针对癫痫和阿尔茨海默病的药物的脑生物利用度，这是两种常见的破坏性神经系统疾病。我们正在探索可逆调节血脑屏障（BBB） p -糖蛋白（P-gp）活性的方法。在体内研究表明，缬草碱（PSC833）在血脑屏障处对P-gp的药理抑制增加了抗癫痫药苯妥英（P-gp的一种底物）在大脑中的摄取。我们建议在P-gp治疗药物本身的基础上开发新的二聚体前药抑制剂。一旦进入大脑，这些二聚体前药将恢复为已知的经批准的治疗剂。我们假设，二聚体前药抑制剂与单体药物的治疗剂量联合使用将有助于增加大脑中治疗剂的水平，并可能降低患者的总体剂量水平。我们相信，我们已经组建了一支经验丰富的pi团队，可以实现每一个具体目标。具体目标1：我们将合成抗癫痫药物（AEDs）（苯妥英、苯巴比妥和拉莫三嗪）、抗阿尔茨海默病药物（加兰他明）和一种潜在的抗阿尔茨海默病药物（格列卫）的前药二聚体，它们通过无迹连接连接。具体目标2：我们将利用各种细胞系来评估前药二聚体对P-gp转运的抑制作用，这些细胞系过度表达P-gp或在体内内源性水平表达P-gp。特异性目标3：我们将评估前药二聚体对荧光底物道诺霉素、钙黄蛋白am、Bodipy-FL-verapamil和罗丹明123在离体大鼠脑毛细血管中P-gp转运的抑制作用，并将治疗性单体作为对照。在拟议的资助期结束时，我们将在脑内皮细胞和脑毛细血管模型中获得具有抗p -糖蛋白活性的二聚体前药。这项研究的长期目标将是在癫痫小鼠模型中监测抗癫痫药和抗阿尔茨海默病药物与活性前药联合使用的脑渗透。治疗脑部疾病是有问题的，因为许多药物不能进入大脑。大脑无法穿透的部分原因是大脑屏障上有一个泵，在大脑进入之前将药物移除。这项提议试图通过暂时阻断泵使药物进入大脑来解决这个问题。这些研究的完成有可能改善癫痫和阿尔茨海默病的治疗。